It is clear that a SPoT is advantageous to all stakeholders in the pharmaceutical ecosystem.

Pharmaceutical companies spend substantially less time and money on the processes for medicinal product information (new as well as revisions), as they enter data once in a controlled manner and can process updates more easily. The approval process with the regulator is easier and more efficient.

Regulators save time and money, as SPoT streamlines the approval process and requires less manual labor. After all structure and consistency do not have to be checked manually anymore.

Healthcare providers using SPoT can be certain that the data are complete, consistent, approved and up to date. This means that there is always a digital source of knowledge that is correct. That is why SPoT is also called the Single Point of Trust. Also, application of medicinal product information in a diversity of output formats, is much more easy.

Ultimately, the end user of a pharmaceutical product benefits greatly: as high-quality information is readily available to patients and healthcare providers, more time and financial resources are available for a personalized approach, personalized care and patient oriented innovation.